Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Read more
Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Read more
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Read more
European Commission Approves Pfizer’s EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options Read more
Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments Read more
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease Read more
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours Read more
FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Read more